Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1464–1468. doi: 10.1128/aac.35.7.1464

Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice.

A Braitman 1, M R Swerdel 1, S J Olsen 1, A V Tuomari 1, J S Lynch 1, B Blue 1, T Michalik 1, A K Field 1, D P Bonner 1, J M Clark 1
PMCID: PMC245191  PMID: 1656863

Abstract

The new antiviral nucleoside SQ 34,514 [(1R-1 alpha, 2 beta, 3 alpha)-2-amino-9- [2,3-bis(hydroxymethyl)cyclobutyl]-6H-purin-6-one], the active R isomer of racemic SQ 33,054 (cyclobut-G), was evaluated for efficacy in the treatment of herpesvirus infections in mice. SQ 34,514 was orally efficacious in a herpes simplex virus type 1 (HSV-1) systemic infection, an intracerebral HSV-2 infection, a vaginally induced HSV-2 infection in ovariectomized mice, and in a systemic murine cytomegalovirus infection. SQ 34,514 compared favorably with acyclovir and ganciclovir in the treatment of these experimental infections. In mice, SQ 34,514 had an oral bioavailability of 80% based on urinary excretion. SQ 34,514 may have potential value in the therapy of HSV and cytomegalovirus infections in humans.

Full text

PDF
1464

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bisacchi G. S., Braitman A., Cianci C. W., Clark J. M., Field A. K., Hagen M. E., Hockstein D. R., Malley M. F., Mitt T., Slusarchyk W. A. Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogues. J Med Chem. 1991 Apr;34(4):1415–1421. doi: 10.1021/jm00108a026. [DOI] [PubMed] [Google Scholar]
  2. De Clercq E. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother. 1982 Apr;21(4):661–663. doi: 10.1128/aac.21.4.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Drew W. L. Cytomegalovirus infection in patients with AIDS. J Infect Dis. 1988 Aug;158(2):449–456. doi: 10.1093/infdis/158.2.449. [DOI] [PubMed] [Google Scholar]
  4. Field A. K., Davies M. E., DeWitt C. M., Perry H. C., Schofield T. L., Karkas J. D., Germershausen J., Wagner A. F., Cantone C. L., MacCoss M. Efficacy of 2'-nor-cyclicGMP in treatment of experimental herpes virus infections. Antiviral Res. 1986 Oct;6(6):329–341. doi: 10.1016/0166-3542(86)90015-x. [DOI] [PubMed] [Google Scholar]
  5. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Field A. K., Tuomari A. V., McGeever-Rubin B., Terry B. J., Mazina K. E., Haffey M. L., Hagen M. E., Clark J. M., Braitman A., Slusarchyk W. A. (+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses. Antiviral Res. 1990 Jan;13(1):41–52. doi: 10.1016/0166-3542(90)90043-7. [DOI] [PubMed] [Google Scholar]
  7. Fletcher C., Sawchuk R., Chinnock B., de Miranda P., Balfour H. H., Jr Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986 Sep;40(3):281–286. doi: 10.1038/clpt.1986.177. [DOI] [PubMed] [Google Scholar]
  8. Hayashi S., Norbeck D. W., Rosenbrook W., Fine R. L., Matsukura M., Plattner J. J., Broder S., Mitsuya H. Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro. Antimicrob Agents Chemother. 1990 Feb;34(2):287–294. doi: 10.1128/aac.34.2.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Matthews T., Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S490–S494. doi: 10.1093/clinids/10.supplement_3.s490. [DOI] [PubMed] [Google Scholar]
  10. Norbeck D. W., Kern E., Hayashi S., Rosenbrook W., Sham H., Herrin T., Plattner J. J., Erickson J., Clement J., Swanson R. Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. J Med Chem. 1990 May;33(5):1281–1285. doi: 10.1021/jm00167a002. [DOI] [PubMed] [Google Scholar]
  11. O'Brien J. J., Campoli-Richards D. M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233–309. doi: 10.2165/00003495-198937030-00002. [DOI] [PubMed] [Google Scholar]
  12. Overall J. C., Jr, Kern E. R., Glasgow L. A. Effective antiviral chemotherapy in cytomegalovirus infection of mice. J Infect Dis. 1976 Jun;133 (Suppl):A237–A244. doi: 10.1093/infdis/133.supplement_2.a237. [DOI] [PubMed] [Google Scholar]
  13. Richards J. T., Kern E. R., Overall J. C., Jr, Glasgow L. A. Differences in neurovirulence among isolates of Herpes simplex virus types 1 and 2 in mice using four routes of infection. J Infect Dis. 1981 Nov;144(5):464–471. doi: 10.1093/infdis/144.5.464. [DOI] [PubMed] [Google Scholar]
  14. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Verheyden J. P. Evolution of therapy for cytomegalovirus infection. Rev Infect Dis. 1988 Jul-Aug;10 (Suppl 3):S477–S489. doi: 10.1093/clinids/10.supplement_3.s477. [DOI] [PubMed] [Google Scholar]
  16. Whitley R. J., Alford C. A., Hirsch M. S., Schooley R. T., Luby J. P., Aoki F. Y., Hanley D., Nahmias A. J., Soong S. J. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986 Jan 16;314(3):144–149. doi: 10.1056/NEJM198601163140303. [DOI] [PubMed] [Google Scholar]
  17. Woolf N. K., Ochi J. W., Silva E. J., Sharp P. A., Harris J. P., Richman D. D. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob Agents Chemother. 1988 Jun;32(6):865–872. doi: 10.1128/aac.32.6.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. de Miranda P., Krasny H. C., Page D. A., Elion G. B. The disposition of acyclovir in different species. J Pharmacol Exp Ther. 1981 Nov;219(2):309–315. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES